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In May 2010, the sixty-third World
Health Assembly adopted resolution
WHA63.20 on the control and elimination
of Chagas disease, highlighting the need
‘‘to promote the development of public
health measures in disease-endemic and
disease non-endemic countries, with spe-
cial focus on endemic areas, for the early
diagnosis of congenital transmission and
management of cases’’ [1]. This article
summarizes the recommendations of the
Technical Group IVa on ‘‘Prevention and
Control of Congenital Transmission and
Case Management of Congenital Infec-
tions’’ of the World Health Organization’s
Programme on Control of Chagas disease
(infection with Trypanosoma cruzi). The
present recommendations derive from
those obtained in the meetings listed in
Box 1.
Preliminary Considerations on
Congenital Transmission of T.
cruzi Infection
Congenital transmission of T. cruzi
infection is considered as such (i) when a
neonate is born from an infectious mother
(that is, a mother with positive serology or
T. cruzi parasites circulating in the blood),
and (ii) when T. cruzi parasites are
identified at birth, or (iii) when T. cruzi
parasites or specific antibodies not of
maternal origin are detected after birth,
and when previous transmission to infant
by vectors and blood transfusion has been
ruled out [2,3].
Congenital transmission occurs in areas
where the disease is endemic as well as in
areas where vector transmission has been
interrupted, in areas where the disease is
non-endemic, and from one generation to
another. This pattern of transmission
facilitates uncontrolled spread of the
parasite infection for long periods of time
[2,3].
According to epidemiological data from
Latin America, the estimated number of
cases of congenital T. cruzi infection is
.15,000 per year [4]. The incidence of
congenital cases in non-endemic areas is
not known, although several reports attest
to its occurrence [5,6].
Although some congenital cases can
present non-specific symptoms as is seen
in congenital infections with Toxoplasma
gondii, rubella virus, cytomegalovirus, and
herpes simplex virus (commonly identified
in the acronym TORCH), most cases are
asymptomatic. This warrants a control
strategy of mandatory screening for con-
genital infection based on laboratory
diagnosis [2,3,7,8,9].
Congenital T. cruzi infection is an acute
infection in newborns that should be
treated with anti-parasitic therapy. Left
untreated, the infection can progress to
chronic Chagas disease later in life.
Prevention of Congenital
Transmission
For pregnant women who are already
infected with T. cruzi, there is no specific or
direct means of preventing congenital
infection. Since the teratogenic risks of
the available medicines (benznidazole and
nifurtimox) are not well known and the
risk of adverse reactions is high in adults,
anti-parasitic treatment is not recom-
mended during pregnancy.
For women who are not pregnant,
prevention of congenital transmission is
possible by (i) treating infected women
aged #15 years and infected women of
fertile age who are living or have lived in
disease-endemic areas [10] (outside lacta-
tion periods to avoid interruption of
lactation as a result of possible adverse
reactions to medicines [11]); and (ii)
control of vectors and blood transmission
in disease-endemic areas to reduce the risk
of infection and the reservoir of infected
women [12].
Antenatal Screening
Screening should be carried out during
pregnancy to detect mothers who are
infectious and at risk of transmitting
infection to their foetuses. There is no
way to identify, in advance, those mothers
who will transmit the infection to their
fetuses.
Serological testing is recommended for
pregnant women (i) who are living in
disease-endemic areas, (ii) who are living
in disease non-endemic areas and have
occasionally received blood transfusion in
disease-endemic areas, and (iii) who are
living in disease non-endemic areas and
are born or have lived previously in
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were born in such areas.
Diagnostic Methods
Detection of Infection during
Pregnancy
Detection of infection during pregnancy
can be performed using two conventional
serological tests: indirect immunofluores-
cence assay (IFA); enzyme-linked immu-
nosorbent assay (ELISA). These diagnostic
tests are generally available at low cost in
primary health care facilities; however,
they have to be performed in a laboratory
and the results are not immediately
available [13,14].
Rapid diagnostic methods (such as in-
munochromatographic, immunodot, and
immunofiltration tests) are necessary for
pregnant women entering maternity facil-
ities for delivery without previous serodi-
agnosis, or at primary health care facilities
in rural endemic areas. These screening
tests are quickly performed, but they have
not been validated at large scale and need
confirmation with standard serological
tests [15,16].
Detection of Congenital Infection in
Neonates
Detection of congenital infection in
neonates can be performed by detecting
living parasites in the blood (umbilical
cord blood or venous blood of the
newborn). Parasitological techniques that
concentrate parasites by centrifugation
can be performed using capillary tubes
(microhematocrit test; investigation of
parasites by microscopic examination of
blood buffy coat can be done directly into
the tube, avoiding its cutting, which was
susceptible to contaminating the examin-
er), or Eppendorf tubes (microstrout).
These tests offer rapid and definitive
diagnosis allowing for rapid initiation of
treatment. However, they require skilled
personnel and assured quality control,
which may not be available in primary
health care facilities in rural endemic areas
[2,3,17].
Polymerase chain reaction (PCR) is
under evaluation and has not been
validated yet for the diagnosis of congen-
ital infection, although it might improve its
early detection [9,18,19]. It is not available
at primary health care facilities in endemic
areas and has to be reserved for specialised
centres.
Detection of Congenital Infection in
Infants Aged .8 Months
Detection of congenital infection in
infants aged .8 months (when maternal
antibodies have disappeared) can be
performed by detecting T. cruzi–specific
antibodies using serological tests, as for
mothers. These tests are available at
primary health care facilities. However,
their performance in infants aged .8
months of age delays diagnosis and
treatment. A negative serological result in
infants below 8 months of age indicates an
absence of congenital infection.
Detection of blood parasites at any time
after birth or a positive T. cruzi–specific
serology in infants aged .8 months are
the gold standards for diagnosis of con-
genital Chagas disease (when previous
transmission by vectors and blood trans-
fusion has been ruled out, see above).
Health systems should evaluate the
strategy that facilitates the earliest possible
diagnosis of congenital infection.
Treatment of Neonates and
Infants
Cases of congenital T. cruzi infection
should be treated as soon as the diagnosis
has been confirmed.
Although randomised comparative clin-
ical trials have not been carried out, the
experience of expert clinical groups in
treating congenital T. cruzi infection indi-
cates that (i) both benznidazole and
nifurtimox can be used to treat congenital
cases; (ii) the recommended dose of
benznidazole in infants, as in adults, is
5–7 mg/kg per day; doses of benznidazole
up to 10 mg/kg per day can be used in
neonates and infants aged ,1 year [12];
the recommended doses of nifurtimox in
neonates and infants are 10–15 mg/kg per
day; (iii) such doses can be administered
orally in one dose in low-weight neonates
or, preferably, in divided doses of two to
three sub-doses; precautions should to be
taken to obtain appropriate dosage of
active drug, since the currently available
tablets have to be crushed and used as a
suspension; (iv) the recommended dura-
tion of treatment is 60 days and should not
be ,30 days; (v) benznidazole, which is
manufactured by Laborato ´rio Farmace ˆu-
tico do Estado de Pernambuco (LAPEFE,
Brazil), is available in tablets of 100 mg
through ‘‘Masters’’ (Davie, Florida, United
States; Elstree, Hertfordshire, United
Kingdom), the World Health Organiza-
tion (WHO), and the Pan American
Health Organization (PAHO). To facili-
tate the preparation of paediatric suspen-
sions, benznidazole should also be avail-
able in dispersal tablets of 12.5 mg.
Nifurtimox is manufactured by Bayer
and is available in tablets of 120 mg
through WHO and PAHO.
Treatment is generally successful and
without the adverse reactions seen in
adults if administered within the first year
of life [20].
Care of Infected Mothers and
Their Other Infected Children
The clinical forms of maternal T. cruzi
infection (particularly the cardiac and
digestive forms) require further evaluation
[12]. Since etiological treatment of infect-
Box 1. Meetings from Which the Present Recommendations
Derive
N Meeting ULB (Belgium)/UMSS (Bolivia)), Cochabamba, Bolivia, November 6–8,
2002: ‘‘Congenital Infection with Trypanosoma cruzi: From Mechanisms of
Transmission to Strategies for Diagnosis And Control’’, Carlier Y and Torico F,
Revista da Sociedade Brasileira de Medicina Tropical 2003, 6: 767–771.
N Meeting PAHO/CLAP/ULB (Belgium)/IRD (France), Montevideo, Uruguay, June
24–25, 2004: ‘‘Congenital Chagas Disease: Its Epidemiology and Management’’,
http://www.paho.org/English/AD/DPC/CD/dch-chagas-congenita-2004.htm
N Meeting PAHO/CLAP/ULB (Belgium), Montevideo, Uruguay, May 17–18, 2007:
‘‘Information, Education and Communication in Congenital Chagas Disease’’,
http://www.paho.org/English/AD/DPC/CD/dch-congenita-iec-07.doc
N Meeting WHO, Geneva, Switzerland, July 4–6, 2007: ‘‘Revisiting Chagas Disease:
From a Latin American Health Perspective to a Global Health Perspective’’
N Meeting of the WHO TG IVa (congenital and paediatric Chagas disease), New
Orleans, Louisiana, United States, December 11, 2008, satellite meeting to the
ASTMH 57th annual meeting
N Meeting of the 6th European Congress of Tropical Medicine and International
Health, Verona, Italy, September 6–10, 2009: ‘‘Chagas Disease in Europe’’
N Meeting of WHO-HQ and the WHO regional office for Europe, Geneva,
Switzerland, December 17–18, 2009: ‘‘Consultation on Chagas Disease in
Europe’’
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pregnancy, treatment should be consid-
ered after delivery and breastfeeding.
It is recommended that infected moth-
ers do not donate blood. Medical evalua-
tion with electrocardiography should be
performed regularly to follow the clinical
evolution of the disease.
Chagas disease should be systematically
investigated in siblings and relatives of
infected mothers (serological investiga-
tion), and positive cases should be clini-
cally evaluated and treated accordingly.
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